This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Buy These 5 Stocks With Attractive Sales Growth Right Away
by Zacks Equity Research
Sales growth is a vital measure for any corporate house, as it is important to growth projections and strategic decision-making.
Raymond James (RJF) Down 2.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Raymond James (RJF) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Higher Costs Hurt Raymond James (RJF) Profits: Time to Sell?
by Zacks Equity Research
Raymond James' (RJF) bottom line is likely to be hurt by continuously rising expenses. The lack of geographic diversification also remains a concern.
Raymond James' (RJF) Q3 Earnings Miss on Dismal Trading
by Zacks Equity Research
Disappointing trading performance hurts Raymond James' (RJF) Q3 earnings. However, solid M&As and higher interest rates provide some support.
Investment Managers Earnings Due on Jul 25: TROW, RJF & More
by Zacks Equity Research
Investment managers are likely to gain from higher assets under management & advisory activities in the April-June quarter. Yet, return of normalized client activities might offset the positives.
Investment Banking to Aid Raymond James (RJF) Q3 Earnings
by Zacks Equity Research
Given the strength in investment banking and normalized trading levels, Raymond James' (RJF) earnings will likely improve in Q3.
Schwab (SCHW) Beats Q2 Earnings on Higher Interest Income
by Zacks Equity Research
Schwab's (SCHW) Q2 earnings reflect benefits from higher interest rates and improving trading activity.
Rising Costs Curb Raymond James' (RJF) Profits: Time to Sell?
by Zacks Equity Research
Rising expenses and lack of geographic diversification remain major causes of concern for Raymond James (RJF), while strategic acquisitions may provide some support.
Why Is Raymond James (RJF) Up 16.4% Since Its Last Earnings Report?
by Zacks Equity Research
Raymond James (RJF) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Trading Rebound to Support Raymond James' (RJF) Q2 Earnings
by Zacks Equity Research
Reversal in trading activities, stable underwriting fees and higher interest rates are expected to support Raymond James' (RJF) Q2 earnings.
Morgan Stanley (MS) Restates Q4 Earnings on U.S. Tax Reform
by Zacks Equity Research
Morgan Stanley (MS) revises its 2017 earnings per share by 2 cents.
Raymond James Financial (RJF) Down 6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Raymond James Financial (RJF) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WisdomTree (WETF) Shares Fall on Q4 Earnings Miss, Costs Up
by Zacks Equity Research
WisdomTree Investments (WETF) Q4 results reflect higher expenses. Strong advisory fees and assets under management were some positives.
Investment Managers' Earnings on Jan 24: AMP, RJF, LM, SEIC
by Zacks Equity Research
Ameriprise (AMP), Raymond James (RJF), SEI Investments (SEIC) and Legg Mason's (LM) results might benefit from improved investment banking. Yet, fall in trading revenues might be a drag.
Can Underwriting Fees Aid Raymond James (RJF) Q1 Earnings?
by Zacks Equity Research
Driven by improvement in underwriting fees, Raymond James' (RJF) Q1 earnings will likely improve despite trading weakness and lower advisory fees.
Zacks.com highlights: Raymond James Financial, Cognizant Technology Solutions, Applied Materials, Church & Dwight and Total System Services
by Zacks Equity Research
Zacks.com highlights: Raymond James Financial, Cognizant Technology Solutions, Applied Materials, Church & Dwight and Total System Services
5 Best Stocks with Impressive Sales Growth Worth Buying
by Zacks Equity Research
Among several stock-picking strategies, we chose a rational, down-to-earth investment approach - one that focuses on sales growth of a company.
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
by Zacks Equity Research
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
Bet on These 5 PEG-Ratio Based GARP Picks
by Zacks Equity Research
A lower PEG ratio, preferably less than one, is always better for GARP investors.
GAIN Capital (GCAP) in Focus: Stock Moves 5.2% Higher
by Zacks Equity Research
GAIN Capital (GCAP) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Time to Focus on Raymond James (RJF) for Strong Earnings Growth Potential
by Zacks Equity Research
Raymond James (RJF) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
The Zacks Analyst Blog Highlights: MGIC Investment, Moody's, American Express, E*TRADE Financial and Raymond James Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MGIC Investment, Moody's, American Express, E*TRADE Financial and Raymond James Financial
5 Large-Cap Financial Stocks That Crushed the Market in 2017
by Zacks Equity Research
These stocks should continue their stellar run in the New Year on improving industry backdrop and optimism over the movements of the Fed and Trump administration.
SEI Investments Ups Dividend: Is There More Upside Left?
by Zacks Equity Research
SEI Investments' (SEIC) 7% dividend hike reflects its strong balance sheet position. Also, the stock has significant upside potential driven by strong fundamentals.
Franklin (BEN) Announces 15% Dividend Hike: Time to Hold?
by Zacks Equity Research
Franklin announced 15% increase in the quarterly common stock dividend to 23 cents per share. The new dividend will be paid on Jan 10, 2018, to shareholders of record as of Dec 26, 2017.